Search

X‐ray radiography, playing a crucial role in the daily life of humans, extends the application landscapes of perovskites. Lead halide perovskites remain superior candidates because of strong X‐ray absorption and effective conversion of X‐ray to visible photons. Unfortunately, the perovskites exhibiting efficient band‐edge emission (3D, quasi‐2D or 2D) usually suffer from severe self‐absorption, while the perovskites showing broadband emission with large Stokes shift (0D, 1D or 2D) usually have low quantum yield, long afterglow or poor solution‐processability. Halide‐intercalated perovskites, with incorporated halides in organic layers, exhibit attractive optoelectronic properties due to reduced confinement of excitons, but their development falls far behind due to limited molecular design strategies and wet‐chemistry methods. Here, the use of universal‐wet‐chemistry‐synthesized novel halide‐intercalated perovskites as an efficient X‐ray scintillator for X‐ray imaging is reported. These novel perovskites exhibit superior luminescence by exploiting both free and self‐trapped excitons via halide intercalation. Accordingly, such perovskite scintillators present higher radioluminescence performance compared with conventional perovskite scintillators through enhanced radiative recombination and suppressed self‐absorption simultaneously. With such a scintillator screen, high‐performance X‐ray imaging is demonstrated. The results not only represent a universal synthesis route for the development of perovskites, but also provide valuable guidance for high‐performance X‐ray radiography. [ABSTRACT FROM AUTHOR]

Background: Neoadjuvant therapy has become a mainstay of treatment for locally advanced resectable esophageal cancer. The objective of this research was to investigate the effectiveness and safety of neoadjuvant immunotherapy combined with chemotherapy in treating surgically removable esophageal squamous cell carcinoma (ESCC)., Methods: From January 1, 2016 to April 1, 2023, we conducted a retrospective analysis of patients diagnosed with resectable esophageal cancer who underwent neoadjuvant immunotherapy combined with chemotherapy at The First Affiliated Hospital of Nanchang University. The primary endpoints of this study were pathologic complete response (pCR), major pathologic response (MPR) and disease-free survival (DFS). The secondary endpoints of this study were overall survival (OS), objective response rate (ORR) and safety., Results: A total of 122 patients with ESCC receiving neoadjuvant immune-chemotherapy (nICT) were included. Fifty-four patients achieved partial response (PR) and two patients achieved complete response (CR), with an ORR of 45.9%. Of the 106 patients who underwent surgery, a total of 28 patients achieved pCR (26.4%) and a total of 37 patients achieved MPR (34.9%). Grade 3 or higher adverse events occurred in 26 patients (21.3%). The most common postoperative complication was pneumonitis (25.5%)., Conclusions: Neoadjuvant immunotherapy combined with chemotherapy demonstrates satisfactory efficacy in the treatment of locally advanced ESCC, with manageable treatment-related adverse events and postoperative complications., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-169/coif). The authors have no conflicts of interest to declare., (2024 Journal of Thoracic Disease. All rights reserved.)